RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Enzymatically Switchable Pyroptosis-Inducing Polymer Conjugate to Coordinate Host Immune Responses in Cancer Immunotherapy.
Enzymatically Switchable Pyroptosis-Inducing Polymer Conjugate to Coordinate Host Immune Responses in Cancer Immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
Gasdermin-D介导的细胞焦亡是一种主要发生在抗原呈递细胞中的免疫原性细胞死亡,在协调固有免疫和适应性免疫中起关键作用。
因此,这一动态过程作为有效的癌症免疫治疗策略具有巨大潜力。然而,在癌症中对其进行充分的时空控制仍具有挑战性。本文报道了一种酶可切换的焦亡诱导聚合物偶联物(EPIC),该偶联物在癌细胞中丰富的Cathepsin B存在下,可选择性地在溶酶体中触发化学发光共振能量转移(CRET)。在体外暴露于癌细胞时,EPIC通过自焚介导的CRET产生活性氧,触发溶酶体膜解体,随后激活切割gasdermin-D的信号级联反应。被切割的gasdermin-D在癌细胞膜上形成焦亡孔,促进损伤相关分子模式和炎性细胞因子的外排。当全身给药至荷瘤小鼠时,EPIC通过促进树突状细胞成熟和重新激活细胞毒性NK细胞,引发强烈的免疫反应。EPIC与抗PD-1抗体联合使用增强了肿瘤特异性细胞毒性T细胞的浸润并促进了记忆T细胞,从而使已建立的肿瘤获得持久缓解,超过一半的受治小鼠实现完全肿瘤消退。
总体而言,EPIC作为一种具有多方面优势的纳米平台,在精准有效的癌症免疫治疗方面具有潜力。
Gasdermin-D-mediated pyroptosis, an immunogenic cell death predominantly occurring in antigen-presenting cells, is pivotal in orchestrating innate and adaptive immunity.
Therefore, this dynamic process holds significant potential as an effective cancer immunotherapy strategy.
However, its adequate spatiotemporal control in cancer remains challenging. An Enzymatically switchable Pyroptosis-Inducing polymer Conjugate (EPIC) is reported that selectively triggers chemiluminescence resonance energy transfer (CRET) in the lysosome in the presence of Cathepsin B, abundant in cancer cells. When exposed to cancer cells in vitro, EPIC generates reactive oxygen species via self-immolation-mediated CRET, triggering lysosomal membrane disintegration, followed by activation of the signaling cascade that cleaves gasdermin-D.
Cleaved gasdermin-D forms pyroptotic pores in the cancer cell membrane, promoting the efflux of damage-associated molecular patterns and inflammatory cytokines. When systemically administered into the tumor-bearing mice, EPIC provokes a robust immune response by promoting dendritic cell maturation and reinvigorating cytotoxic NK cells.
Combination of EPIC with anti-PD-1 antibody enhanced infiltration of tumor-specific cytotoxic T cells and promoted memory T cells, resulting in a durable remission of established tumors with complete tumor regression in more than half of the treated mice.
Overall, EPIC has potential as a nanoplatform with multifaceted advantages for precise and effective cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。